Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
14.023 / 17.032
#112177

Re: Farmas USA

SYNERGY PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

  • 63,085 TRULANCE 30-count packs were dispensed in the third quarter of 2018, a 104.7% increase versus 30,825 in the prior year quarter, per IQVIA.
  • 23,560 TRULANCE new prescriptions were filled in the third quarter of 2018, a 46.4% increase versus 16,089 in the prior year quarter, per IQVIA.
  • Since the launch on March 20, 2017, 250,684 TRULANCE 30-count packs have been dispensed and normalized prescription volume has increased 38.4% on average quarter-over-quarter, per IQVIA.
  • TRULANCE U.S. net sales were $11.1 million in the third quarter of 2018, a 122.0% increase compared to $5.0 million in the third quarter of 2017.
  • Cash and cash equivalents were approximately $45.6 million at the end of the third quarter of 2018.
  • Synergy is continuing discussions with CRG and has twice received temporary waivers on the minimum market cap covenant, which is set to expire on November 12, 2018 absent further extension. 

https://ir.synergypharma.com/press-releases/detail/1881

#112178

Re: Farmas USA

Qué broker utilizas para cortos?

#112180

Re: Farmas USA

 

Ziopharm +7.7% as earnings delay prompts deal speculation

Nov. 8, 2018 5:56 PM ET|By:  Jason Aycock, SA News Editor 

Ziopharm Oncology (NASDAQ: ZIOP) is ramping higher, up 7.7% on solid postmarket volume, after a sudden postponement of an earnings report set for after the close today.

The company has  rescheduled its conference call to Monday, Nov. 12, at 8 a.m. ET, leading to the prospect that the company's working to close a deal before the earnings release.

It's filing its 10-Q form tomorrow, so any deal may be in the final stages.

Ziopharm earnings estimates

https://seekingalpha.com/news/3407891-ziopharm-plus-7_7-percent-earnings-delay-prompts-deal-speculation?app=1#email_link

#112181

Re: Farmas USA

MLNT 

Los tiburones , han terminado de llenar sus sacas a precios de saldo , asi que ahora Up.. Up, asi lo confirma el MACD diario y el Stokastico en semanal 

Vatera Healthcare Partners LLC    

November 6, 2018

(Date of Event which Requires Filing of this Statement)

SHARED DISPOSITIVE POWER       16,007,237

http://ir.melinta.com/sec-filings/sec-filing/sc-13da/0001193125-18-322611

#112183

Re: Farmas USA

Sgmo

Dentro 11,35

Edito: viendo el tema, vendidas en even y recompradas a 11,05

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?